- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05307744
Lactobacillus Plantarum PS128:n vaikutukset lapsilla, joilla on ASD
Lactobacillus Plantarum PS128:n vaikutukset lapsilla, joilla on autismikirjon häiriö
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that can cause significant social, communication and behavioral deficits. Probiotics are regarded as active microorganisms. With sufficient amounts, probiotics can regulate intestinal flora, intestinal permeability, inflammation and antioxidant reactions in the body. These reactions may further promote health, regulate metabolic disease progression and prevent complications. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal and human studies which modulated the levels of neurotransmitters in different brain areas. This study is to evaluate whether the consumption of PS128 can improve the symptoms of patients with ASD. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in school children with ASD.
Tutkimuksen yleiskatsaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Taoyuan, Taiwan
- Chang Gung Memorial Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- (1) Age 7 to 12 years old.
- (2) PS128 group and placebo group: Children with autism spectrum disorder, confirmed by Autism Diagnostic Observation Schedule.
- (3) Normal control group: Children without autism spectrum disorder.
Exclusion Criteria:
- (1) Receiving antibiotics within one month.
- (2) Probiotics used in powder, capsule, or tablet in two weeks (except for Yogurt, Yogurt, Yakult and other related foods).
- (3) Patients with hepatobiliary gastrointestinal tract who have undergone surgery (except for hernia surgery and appendectomy)
- (4) Those with special diets (gluten-free, casein-free, high-protein, and ketogenic diet).
- (5) Those with a history of cancer.
- (6) Those who are allergic to lactic acid bacteria.
- (7) Not eligible judged by PI
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Nelinkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: PS128
Subjects will take PS128 capsules every day (2 capsules/day, once) for 12 weeks. |
Each PS128 capsule contained >3 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg. |
|
Placebo Comparator: Placebo
Subjects will take placebo capsules every day (2 capsules/day, once) for 12 weeks. |
The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose. |
|
Ei väliintuloa: Normal control
Normal control group are enrolled by invitation from the age and gender matched healthy children. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Changes of Total Scores of Social Responsiveness Scale
Aikaikkuna: Baseline, Week 12 and Week 16
|
Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness. |
Baseline, Week 12 and Week 16
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Changes of Total Scores of Repetitive Behavior Scale-Revised
Aikaikkuna: Baseline, Week 12 and Week 16
|
Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Child Behavior Checklist
Aikaikkuna: Baseline, Week 12 and Week 16
|
Child Behavior Checklist is a parents' report questionnaire for behavioral and emotional problems. The score ranges from 0-240. The lower scores stand for better behavioral and emotional regulation. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Adaptive Behavior Assessment System
Aikaikkuna: Baseline, week 12 and Week 16
|
Adaptive Behavior Assessment System is a parents' report questionnaire for adaptive behavior. The score ranges from 9-171. The higher scores stand for better adaptive behavior. |
Baseline, week 12 and Week 16
|
|
Changes in Accuracy of Frith-Happe Animation
Aikaikkuna: Baseline, Week 12 and Week 16
|
A quick and objective test of Theory of Mind. 8 questions in total, the more correct questions stand for better Social Cognition. |
Baseline, Week 12 and Week 16
|
|
Changes in Accuracy of Eyes Task
Aikaikkuna: Baseline, Week 12 and Week 16
|
An advanced test for Theory of Mind. 43 questions in total, the more correct questions stand for better social skills. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Aberrant Behavior Checklist
Aikaikkuna: Baseline, Week 12 and Week 16
|
Aberrant Behavior Checklist is a parents' report questionnaire for aberrant behavior. The score ranges from 0-174. The lower scores stand for less aberrant behavior. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Emotional Dysregulation Inventory
Aikaikkuna: Baseline, Week 12 and Week 16
|
Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The score ranges from 0-120. The lower scores stand for better emotional regulation. |
Baseline, Week 12 and Week 16
|
|
Changes of Total Scores of Parenting Stress Index, Fourth Editon
Aikaikkuna: Baseline, Week 12 and Week 16
|
Parenting Stress Index is a parents' report questionnaire for parenting stress. The score ranges from 0-180. The lower scores stand for lower parenting stress. |
Baseline, Week 12 and Week 16
|
|
Assessment of Clinical Global Impression-Severity of Illness
Aikaikkuna: Week 12 and Week 16
|
The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. The score ranges from 1-7. CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse. |
Week 12 and Week 16
|
|
Assessment of Patient Global Impression of Change
Aikaikkuna: Week 12 and Week 16
|
The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. The score ranges from 1-7. Patients rate their change as "1=very much improved ," "2=much improved," "3=minimally improved," "4=no change," "5=minimally worse," "6=much worse," or "7=very much worse)." |
Week 12 and Week 16
|
|
Gut Microbiota-Relative Abundance of Bifidobacterium Faecale
Aikaikkuna: Baseline and Week 12
|
Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota |
Baseline and Week 12
|
|
MRI T1
Aikaikkuna: Baseline and Week 12
|
Brain structural volumes (cm²). The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time. |
Baseline and Week 12
|
|
Functional MRI (Resting-state/Biological Motion Task) - BOLD Signal
Aikaikkuna: Baseline and Week 12
|
Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time. |
Baseline and Week 12
|
|
Diffusion Tensor Imaging (DTI) - FA
Aikaikkuna: Baseline and Week 12
|
Fractional anisotropy (FA) is a measurement used in DTI, which reflects the movement of water molecules. FA ranges from 0 to 1, the higher FA value may represent more intact axons. The advanced processing and analysis of the MRI data have been outsourced to an external core facility. Due to resource scheduling and the prolonged timeline required for specialized image preprocessing, the data analysis is currently in progress and has not yet been finalized. Therefore, quantifiable results are unavailable for summary in the data table at this time. |
Baseline and Week 12
|
|
Safety Assessment - Albumin
Aikaikkuna: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as albumin (3.5-5.4 g/dl). |
Baseline and Week 12
|
|
Safety Assessment - Total Protein
Aikaikkuna: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as total protein (6.4-8.3 g/dl). |
Baseline and Week 12
|
|
Safety Assessment - ALP
Aikaikkuna: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as ALP (135-320 U/L). |
Baseline and Week 12
|
|
Safety Assessment - Total Bilirubin
Aikaikkuna: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as total bilirubin (0.3-1.2 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - T-Cholesterol
Aikaikkuna: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as T-Cholesterol (<170 mg/dL). |
Baseline and Week 12
|
|
Safety Assessment - Uric Acid
Aikaikkuna: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as uric acid (<7.0 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - BUN
Aikaikkuna: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as BUN (7-25 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - Creatinine
Aikaikkuna: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as creatinine (0.2-1.0 mg/dl). |
Baseline and Week 12
|
|
Safety Assessment - AST
Aikaikkuna: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as AST (13-40 U/L). |
Baseline and Week 12
|
|
Safety Assessment - ALT
Aikaikkuna: Baseline and Week 12
|
Safety is assessed function of liver and kidney such as ALT (7-40 U/L). |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - MPO
Aikaikkuna: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - MPO (ng/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-1β
Aikaikkuna: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - IL-1β (pg/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - TGF-β1
Aikaikkuna: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - TGF-β1 (pg/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - Eotaxin
Aikaikkuna: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - Eotaxin (pg/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Inflammatory Changes - IL-6
Aikaikkuna: Baseline and Week 12
|
Inflammatory is assessed via a composite measure of circulating cytokines - IL-6 (ng/mL) |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Serotonin
Aikaikkuna: Baseline and Week 12
|
Oxidative stress is assessed via Serotonin (ng/mL). |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - GABA
Aikaikkuna: Baseline and Week 12
|
Oxidative stress is assessed via GABA (μmol/L). |
Baseline and Week 12
|
|
Change in Levels of Exploratory Blood-based Biomarkers for Oxidative Stress Changes - Cortisol
Aikaikkuna: Baseline and Week 12
|
Oxidative stress is assessed via Cortisol (6-10am 4.82-19.5, 4-8pm 2.47-11.9, μg/dl). |
Baseline and Week 12
|
|
Gut Microbiota-Relative Abundance of Lactiplantibacillus Plantarum
Aikaikkuna: Baseline and Week 12
|
Collect the DNA of fecal flora to test the diversity and abundance of gut microbiota as well as short chain fatty acids in Stool samples. The 16S rRNA gene amplicons will be prepared following the Illumina protocol for preparing the 16S metagenomic sequencing library. Values represent percentages and range from 0 to 100%, with higher values indicating a higher relative abundance of the target bacterium in the gut microbiota. |
Baseline and Week 12
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 202101416A3
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .